The prevalence of obesity-associated nonalcoholic fatty liver disease has significantly increased over the past decade, and end-stage liver disease secondary to nonalcoholic steatohepatitis has become 1 of the most common indications for liver transplantation. This both increases the demand for organs and decreases the availability of donor livers deemed suitable for transplantation. Although in the past many steatotic livers were discarded due to concerns over enhanced susceptibility to ischemia/reperfusion injury (IRI) and organ failure, the discrepancy between supply and demand has resulted in increasing use of expanded criteria donor organs including steatotic livers. However, it remains controversial whether steatotic livers can be safely used for transplantation and how best to improve the performance of steatotic grafts. We aimed to evaluate the impact of diet-induced hepatic steatosis in a murine model of IRI. Using a diet of high trans-fat, fructose, and cholesterol (HTF-C) and a diet high in saturated fats, sucrose, and cholesterol (Western diet), we were able to establish models of mixed macrovesicular and microvesicular steatosis (HTF-C) and microvesicular steatosis (Western). We found that the presence of hepatic steatosis, whether it is predominantly macrovesicular or microvesicular, significantly worsens IRI as measured by plasma alanine aminotransferase levels and inflammatory cytokine concentration, and histological evaluation for necrosis. Additionally, we report on a novel finding in which hepatic IRI in the setting of steatosis results in the induction of the necroptosis factors, receptor interacting protein kinase (RIPK) 3, RIPK1, and mixed-lineage kinase domain-like. These data lay the groundwork for additional experimentation to test potential therapeutic approaches to limit IRI in steatotic livers by using a genetically tractable system. Liver Transplantation 24 908-921 2018 AASLD.
The worldwide prevalence of obesity has dramatically increased over the past 2 decades. In the United States, about a third of the adult population is considered obese, (1) and worldwide, the prevalence is estimated to be approximately 13%. (2) Obesity is associated with a range of cardiometabolic problems including coronary artery disease, insulin resistance, and nonalcoholic fatty liver disease (NAFLD). (3) As the prevalence of obesity has grown, there has been a concomitant increase in NAFLD, with a worldwide prevalence of approximately 20%. (4) NAFLD encompasses a spectrum of liver disease ranging from simple steatosis to varying degrees of inflammation and fibrosis (nonalcoholic steatohepatitis; NASH). Individuals with NASH are then at increased risk of developing cirrhosis and hepatocellular carcinoma. (5) Over the past 2 decades the number of liver transplant recipients with a diagnosis of cirrhosis secondary to NASH has been increasing steadily. (6) Furthermore, with successful treatment of hepatitis C virus readily available, it is predicted that end-stage liver disease secondary to NASH will become the most common indication for liver transplantation by 2020. (6) The higher prevalence of NASH increases the demand for organs while also placing a strain on the donor pool because many steatotic livers are deemed unsuitable for transplantation. One study found 5%-15% of potential living donors have some degree of steatosis, (7) and another study found 21% of cadaveric donors have at least moderate steatosis. (8) A retrospective study found that 40% of discarded grafts were rejected because of the presence of steatosis. (9) Because of the growing discrepancy between supply and demand, there has been increased use of marginal or expanded criteria donors such as older donor age, donation after cardiac death, and mild-to-moderate steatosis. (10) Steatotic livers are considered to be marginal donors by some transplant centers (10) because of concern for increased susceptibility to ischemia/reperfusion injury (IRI) resulting in greater organ damage. (11) (12) (13) (14) (15) (16) (17) (18) It is thought that this results in inferior graft and patient survival as well as higher rates of initial poor function and primary nonfunction. (19) (20) (21) Although rodent studies have consistently shown worse liver injury in the setting of steatosis, these studies are limited by the use of genetic models of obesity and use of highly nonphysiological diets such as the methionine cholinedeficient (MCD) diet. (22) Furthermore, this may be controversial in humans because there are some reports that suggest no significant difference in complications (23) or patient and graft survival. (24) Unfortunately, much of the data in clinical studies used to support the idea that steatosis increases vulnerability to IRI are based on retrospective studies with variable definitions and degrees of steatosis. Some data suggest that macrovesicular steatosis, defined as the presence of a lipid droplet leading to displacement of the nucleus, is generally associated with poor outcomes and to be more injurious to the liver. However, microvesicular steatosis, defined as the presence of multiple lipid droplets without displacement of the nucleus, is thought to result in less liver injury during ischemia/reperfusion (I/R). (8, 17, 23, 25) The factors that drive these 2 types of steatosis are poorly understood, and the concept that microvesicular steatosis is benign has not been examined in detail.
Herein, we used 2 different murine models of dietinduced obesity to create variable degrees of hepatic steatosis and inflammation to characterize its effects on hepatic IRI. Fortuitously, 1 high-fat diet (HFD) chosen for this study produced macrovesicular and microvesicular steatosis, whereas the other produced predominantly microvesicular steatosis. Interestingly, we found that regardless of the HFD composition, the type of steatosis produced, or the degree of preexisting inflammation, feeding mice these HFDs that produced hepatic steatosis exacerbated liver injury. Interestingly, we also found that the presence of steatosis was associated with induction of necroptosis markers after IRI. Evaluating these mouse models also lays the groundwork for examining potential therapeutic interventions that could be tested to improve the function of marginal organs due to steatosis.
Materials and Methods

ANIMAL STUDY DESIGN
Male 5-week-old C57BL/6J mice were purchased from Jackson Laboratory (Bar Harbor, ME). They were allowed to acclimate for 1 week on standard chow diet. They were then placed on a low-fat (LF) control diet (D12450B; Research Diets Inc., New Brunswick, NJ); high trans-fat, fructose, and cholesterol (HTF-C) diet (D09100301; Research Diets Inc.); or a high saturated fat "Western" diet (Western; TD 88137; Envigo, Huntingdon, United Kingdom). Body weight was checked weekly. Mice were maintained on the diet for 8 weeks prior to surgery. All animal studies were approved by the institutional animal use and care committee of Washington University School of Medicine and comply with the Guide for the Care and Use of Laboratory Animals as outlined by the National Academy of Sciences.
HEPATIC I/R SURGERY
Hepatic ischemia was induced using a 70% ischemia model as previously described. (26) Briefly, mice were anesthetized using isoflurane inhalation. Sustained release buprenorphine and bupivacaine were used for analgesia. A midline laparotomy was performed to expose abdominal contents. Hepatic ischemia was induced by cross-clamping the hepatic artery, portal vein, and bile duct distal to the branch point to the right lateral lobe to induce ischemia to the median and left lobes. The clamp was released after 60 minutes followed by 4 hours or 24 hours of reperfusion. Mice undergoing sham surgery underwent a midline laparotomy and were maintained under anesthesia for 60 minutes without cross-clamping of the hepatic artery and portal vein. Mice were allowed to recover for either 4 or 24 hours. At those specified times, mice were euthanized by CO 2 asphyxiation and plasma and liver samples were collected. A portion of the left lobe was preserved in 10% neutral buffered formalin for histological evaluation. The remaining liver samples were immediately frozen in liquid nitrogen and then stored at -80 8C for future analysis. Blood samples were collected from the inferior vena cava at the time of death and plasma collected by centrifugation.
PLASMA PARAMETERS
Tail blood glucose was measured by using a OneTouch Ultra glucometer (LifeScan, Milpitas, CA). Plasma insulin was quantified by an immunoassay (Singulex, Alameda, CA) by the Core Laboratory for Clinical Studies at Washington University. Plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured using commercially available colorimetric kinetic assays (Teco Diagnostics, Anaheim, CA) according the manufacturer's instructions. Plasma tumor necrosis factor a (TNF-a) level was measured using a commercially available enzymelinked immunosorbent assay kit (R&D systems, Minneapolis, MN). Plasma levels of interleukin (IL) 6 were determined, per manufacturer's protocol, with a commercially available magnetic bead suspension assay (MilliporeSigma, Billerica, MA) using the Luminex 200 analyzer (Luminex Corp., Austin, TX).
TRIGLYCERIDE ASSAY
A portion of the caudate lobe (nonischemic) was obtained at time of death. Liver samples were then homogenized in saline followed by the addition of 1% 
WESTERN BLOT ANALYSIS
For Western blot analysis, liver protein extracts were obtained from the liver using the following buffer: 15 mM NaCl, 20 mM trishydroxymethylaminomethane, 1 mM ethylene diamine tetraacetic acid, 0.2% nonidet P-40 (NP-40), and 10% glycerol. Lysates were normalized to protein concentration, denatured, and run on Criterion precast polyacrylamide gel electrophoresis (PAGE) gels (Bio-Rad, Hercules, CA) and transferred onto polyvinylidene fluoride membranes. Antibodies to receptor interacting protein kinase (RIPK) 3 (1:1000; 2283, ProSci, Poway, CA), tissue inhibitor of metalloproteinase (TIMP) 1 (1:1000; ab38978, Abcam, Cambridge, MA), PhosphoS345-mixed-lineage kinase domain-like (MLKL; 1:1000; ab196436, Abcam, Cambridge, MA), MLKL (1:1000; SAB1302339, Sigma-Aldrich, St. Louis, MO), and tubulin (1:1000; T5168, Sigma-Aldrich, St. Louis, MO) were used according to the manufacturers' instructions. Membranes were probed with an antirabbit IRDye 800CW (1:10,000; LI-COR, Lincoln, Nebraska) secondary antibody or an anti-mouse IRDye 700CW secondary antibody (1:10,000; LI-COR). Blots were developed on an infrared Odyssey developer (LI-COR).
HISTOPATHOLOGY AND IMMUNOHISTOCHEMISTRY
A portion of the left lateral lobe was harvested at the time of death and placed in 10% neutral buffered formalin. Formalin-fixed tissues were embedded in paraffin, sectioned, and stained with hematoxylin-eosin (H & E) and/or Masson's trichrome stain. A liver pathologist (I.N.) blinded to the conditions assessed the presence of steatosis and necrosis in the liver specimens. A portion of the left lateral lobe was harvested at the time of death and placed in 10% neutral buffered formalin. Formalin-fixed tissues were embedded in paraffin, sectioned, and stained with H & E and/or Masson's trichrome stain. The H & E slides were reviewed by a liver pathologist (I.N.) in a blinded fashion. Steatosis was assessed as microvesicular and macrovesicular. Microvesicular steatosis was defined as the presence of numerous, small fat vacuoles with a centrally placed hepatocyte nucleus, whereas a large droplet was defined as large or small vacuoles of fat that displace the hepatocyte nuclei. (27) The grade of steatosis and necrosis were assessed as percent area of involvement per slide. The fibrosis stage was assessed based on NASH Clinical Research Network (CRN) criteria. (28) Formalin-fixed and paraffin-embedded tissues were also sectioned and stained for CD68 using 3,3 0 -diaminobenzidine (DAB) immune-peroxidase staining. Anti-CD68 antibody (Abcam, ab125212, 1:500) was incubated overnight at 4 8C. After washing with phosphate-buffered saline (PBS)-Tween20, antirabbit secondary antibody (1:800, 111-064-144, Jackson Laboratory) was applied for 1 hour at room temperature. After washing with PBS-Tween20, slides were incubated with streptavidin-horse radish peroxidase (SA-HRP; 1:1000, 011-030-084, Jackson Laboratory), developed with Betazoid DAB for 3 minutes (BDB2004, Biocare, Pacheco, CA), and counterstained with H & E.
STATISTICAL ANALYSIS
Statistical comparisons were made using a t test. All data are presented as mean 6 standard error of the mean with statistical significance defined as P 0.05. Equality of variances and normality of the data were ascertained through Levene's test and KolmogorovSmirnov tests, respectively. Data from luminex analysis were analyzed via nonparametric analysis of variance Kruskal-Wallis test. When the omnibus test was satisfied, the Mann-Whitney U post-hoc test was used to look for individual diet differences. An alpha level of 0.05 was considered significant.
Results
CHARACTERIZATION OF LF CONTROL AND HFD-FED MICE
We first compared baseline characteristics of mice fed LF or 2 distinct HFDs for 8 weeks. Mice on a LF diet (70% carbohydrate, 20% protein, 10% fat) were compared with mice on a HFD (40% carbohydrate, 20% protein, 40% fat) enriched in trans-fatty acids, fructose, and cholesterol (2%; HTF-C) that was predicted to be the most injurious to the liver. Another group of mice were fed a HFD (42.7% carbohydrate, 15.2% protein, 42% fat) that was primarily saturated fatty acids and did not contain fructose with only 0.2% cholesterol (Western diet). As expected, animals on either HFDs gained significantly more weight than animals fed the LF diet, but mice fed the Western diet also gained significantly more weight than the HTF-C diet-fed mice (Fig. 1A) .
Before death, mice were fasted 4 hours to normalize metabolic variables. Blood glucose concentrations at time of death were not significantly different among the different groups (LF, 167 6 4.9 mg/dL; HTF-C, 164 6 11.8 mg/dL; Western, 170 6 12.2 mg/dL). Western diet-fed mice had higher plasma insulin concentrations compared with both LF and HTF-C dietfed mice (LF, 2114 6 269 pg/mL; HTF-C, 1867 6 327 pg/mL; Western, 3948 6 710 pg/mL; Western diet, P 5 0.04 versus other dietary groups). Both HFD groups had a higher baseline plasma ALT concentration versus LF control mice, and HTF-C diet-fed mice had a significantly higher plasma ALT concentration than Western diet-fed mice (Fig. 1B) .
Both HTF-C-and Western diet-fed mice had a higher liver mass compared with LF control mice (Fig.  1C) . However, mice fed the HTF-C diet had a significantly higher liver weight as determined by percentage of body weight compared with Western diet-fed mice ( Fig. 1C; 6 .8% versus 4.9%; P 5 0.01). Both HFD groups had a higher hepatic triglyceride content than the LF control mice, but they were not significantly different from each other ( Fig. 1D ; P 5 0.33).
We then examined hepatic expression of genes encoding inflammatory cytokines, markers of liver injury, and stellate cell activation (Fig. 1E) . Both the HTF-C-and Western diet-fed mice had significantly elevated expression of the inflammatory cytokine, TNFa, and inhibitors of metalloproteinases, TIMP1 and TIMP3, compared with LF control mice. HTF-C dietfed mice also had a higher expression of genes encoding fibrogenic matrix proteins, Collagen 1a1 (Col1a1), and Collagen 3a1 (Col3a1), than LF control mice, but Western diet-fed mice were not significantly different than LF control mice. Western blot analysis confirmed the increased expression of TIMP1 in HTF-C-and Western diet-fed mice compared with LF controls (Fig.  1F) . HTF-C diet-fed mice had a significantly higher expression of the necroptosis markers, RIPK3 and MLKL, than LF control mice and also had a higher expression of MLKL versus Western diet-fed mice.
THE PATTERN AND CHARACTERISTIC OF HEPATIC STEATOSIS DIFFERS BETWEEN THE HTF-C DIET-FED AND WESTERN DIET-FED MICE
An experienced liver pathologist (I.N.) examined histological specimens in detail and found that although both HFDs result in hepatic steatosis, the degree and pattern of steatosis differed between the 2 diets ( Fig.  2A) . Both HFD-fed groups exhibited moderate to severe steatosis, defined as >30% steatosis (Fig. 2B) . HTF-C diet-fed mouse livers exhibited marked macrovesicular steatosis (26.6%) and microvesicular steatosis (60.8%; Fig. 2B ). In contrast, livers of Western diet-fed mice exhibited predominantly microvesicular steatosis (60.4%) with a small percentage of macrovesicular steatosis (7.6%). Regardless of diet, none of the mice exhibited a significant degree of fibrosis as determined by trichrome stain (Fig. 2C) .
THE PRESENCE OF STEATOSIS LEADS TO INCREASES IN PLASMA ALT AND INFLAMMATORY CYTOKINE LEVELS FOLLOWING I/R SURGERY
We next sought to characterize the response to IRI in mice fed these diets. As in the first experiment, after 8 weeks of HFD feeding, mice on the HTF-C and Western diet again gained significantly more weight and had higher hepatic triglyceride content than mice fed the LF control diet (Supporting Fig. 1A ). Again, mice on the Western diet gained significantly more weight than mice on the HTF-C diet following 8 weeks of diet, but in this cohort of mice, HTF-C diet-fed mice had slightly, but significantly higher, hepatic triglyceride content than Western diet-fed mice (28.4 versus 24.6 mg/g liver; P 5 0.006; Supporting Fig. 1B) . After both 4 and 24 hours of reperfusion, plasma ALT levels were higher in both the HTF-C-and Western diet-fed mice compared with LF controls (Fig. 3A) . At 4 hours, Western diet-fed mice had a significantly higher plasma ALT level than HTF-C diet-fed mice (10,349 versus 6596 U/L; P < 0.001), but at 24 hours, there was no significant difference between the 2 HFD groups (2330 versus 4858 U/L; P 5 0.10). No significant difference in plasma AST was detected among the dietary groups at 4 hours, but at 24 hours, HTF-C diet-fed mice had significantly higher plasma AST levels than LF control mice (2497 versus 1757 U/L; P < 0.05; Supporting Fig. 2 ). Shamoperated mice did not have significantly different plasma AST or ALT levels among the 3 diet groups. We then evaluated plasma concentrations of the inflammatory cytokines, TNF-a, and IL6. We found that the HTF-C diet-fed mice and the Western dietfed mice had higher levels of TNF-a following I/R surgery compared with LF control mice (Fig. 3B) . 
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There was no significant difference in the plasma concentrations of TNF-a between HTF-C-and Western diet-fed mice (5.6 versus 3.8 pg/mL; P 5 0.19). HTF-C diet-fed mice also had higher plasma IL6 concentrations compared with LF diet controls at 24 hours after I/R surgery (Fig. 3C) .
THE PRESENCE OF STEATOSIS LEADS TO INCREASES IN PLASMA ALT AND INFLAMMATORY CYTOKINE LEVELS FOLLOWING I/R SURGERY
Although plasma TNF-a concentrations were increased in HFD mice compared with LF diet-fed mice following I/R surgery, we did not find a significant difference in hepatic expression of TNF-a or IL1b in an ischemic lobe of the liver (Fig. 4A) . Compared with LF controls, the expression of the gene encoding IL6 was increased in HTF-C-and Western diet-fed mice following 4 and 24 hours of reperfusion after I/R surgery (Fig. 4A ). In addition, the expression of the neutrophil marker S100a8 and macrophage marker CD68 were increased in HTF-C-and Western diet-fed mice compared with LF controls 24 hours after surgery (Fig. 4B) .
THE PRESENCE OF STEATOSIS INCREASES THE EXTENT OF NECROSIS AND MACROPHAGE INFILTRATION FOLLOWING I/R SURGERY
Following 4 hours of reperfusion, there is minimal histological evidence of necrosis in the liver specimens of all 3 groups (Supporting Fig. 3) . However, at 24 hours of reperfusion, necrosis became histologically evident (Fig. 5A) . Compared with the LF diet-fed mice, the HTF-C-and Western diet-fed mice had significantly more and larger areas of necrosis (10.0% versus 31.5%, P 5 0.01 and 10.0% versus 46.0%, P < 0.001, respectively). Although the Western diet-fed mice trended toward increased areas of hepatic necrosis compared with the HTF-C-fed mice, this was not statistically significant (46.0% versus 31.5%; P 5 0.17). Immunohistochemical staining for the macrophage marker CD68 demonstrated qualitatively that macrophage infiltration was increased 4 and 24 hours after ischemia by HTF-C and Western diet feeding (Fig. 5B) .
THE PRESENCE OF HEPATIC STEATOSIS IS ASSOCIATED WITH INCREASED EXPRESSION OF NECROPTOSIS MARKERS FOLLOWING I/R SURGERY
Interestingly, we found that hepatic expression of markers of necroptosis (RIPK1, RIPK3, and MLKL) were significantly elevated in the HFD-fed mice compared with LF mice following hepatic I/R surgery (Fig. 6A) . We also found RIPK3 protein levels to be significantly increased in HFD-fed mice at 24 hours compared with LF control mice (Fig. 6B) . Additionally, RIPK3 protein abundance was significantly higher in HTF-C diet-fed mice compared with Western diet-fed mice. The phosphorylation of the RIPK target MLKL also tended to be increased in HTF-C diet-fed mice after I/R surgery. Collectively, these data suggest that feeding mice these HFDs that produce predominantly microvesicular or mixed macrovesicular and microvesicular steatosis in mice exacerbates IRI as assessed by transaminase and inflammatory cytokine levels, necrosis, and necroptotic signaling.
Discussion
In parallel with the growing obesity epidemic, there has also been an increase in the worldwide prevalence of NAFLD. Patients with NASH are more likely than the general population to develop end-stage liver disease, and this has become 1 of the leading causes of liver transplantation in the United States. This places a strain on the field of liver transplantation by both decreasing the availability of nonsteatotic livers as well as increasing the demand for organs. The discrepancy between supply and demand has contributed to increased interest in the use of marginal donors such as steatotic livers. However, their widespread use is limited by uncertainty with respect to safety due to concerns regarding increased susceptibility to IRI in the setting of steatosis. 
LISS ET AL. LIVER TRANSPLANTATION, July 2018
Clinical studies are often limited by their retrospective nature and differing definitions of steatosis. The clinical data have not been convincing as to whether steatosis, especially mild or microvesicular steatosis, results in increased IRI. Thus, multiple animal models have been used to study the impact of hepatic steatosis on IRI. The vast majority of these studies use either genetic models of steatosis or severe diets such as the MCD diet or the 60% HFD. (22) Although genetic models of obesity, such as ob/ob mice, can reliably recreate macrovesicular steatosis, there is concern that hepatic steatosis in genetic models may be different from that associated with metabolic syndrome in humans and that leptin deficiency could have its own effects on ischemic outcomes. (29) The MCD diet can reliably recreate findings consistent with NASH; however, it is not obesogenic, and its systemic metabolic changes do not accurately reflect the metabolic derangements seen in humans affected by obesity. (29, 30) Therefore, although rodent studies have generated fairly convincing data regarding the detrimental impact of hepatic steatosis on IRI, the specific shortcomings of the NAFLD models may limit their interpretation and applicability. Their artificial nature may also limit utility for testing potential therapeutics.
In the present study, we chose 2 different HFD models that produce many features of fatty liver disease to further evaluate the impact of hepatic steatosis on IRI. As expected, mice fed either a HTF-C diet or Western diet gained significantly more weight and had a higher hepatic triglyceride content than mice fed a LF control diet. However, the histological evaluation of liver specimens from mice fed HTF-C versus Western diet revealed qualitative differences in the pattern and distribution of steatosis. The regulation of lipid droplet size is complex. In adipocytes, much more is known regarding lipid droplet formation and size. (31) Although it is known that different pathologic states in the liver are more prone to macrovesicular steatosis or microvesicular steatosis, (32) the factors that regulate this process are poorly understood. It is possible that some component of the HTF-C diet, such as the trans-fat, cholesterol, or fructose, promotes the formation of larger lipid droplets. Herein, the HTF-C diet resulted in marked macrovesicular and microvesicular steatosis, whereas the Western diet created predominantly microvesicular steatosis. We found that the presence of preexisting inflammation and macrovesicular steatosis predictably and significantly worsened IRI. We also found that the presence of microvesicular steatosis was associated with poor tolerance to IRI. Although some clinical studies (8, 23, 25) have advocated for the safe use of livers with microvesicular steatosis, other clinical studies express concern regarding the use of livers with microvesicular steatosis. (33, 34) The discrepancy in data is likely secondary to variable degrees of microvesicular steatosis (ranging from minimal to severe) as well as variability in interpretation of histological samples and differences in clinical variables of donors and recipients.
Our findings and other rodent studies suggest that caution should be applied when concluding that microvesicular steatosis is benign in the context of I/R surgery. (17, 35, 36) Selzner et al. reported lower tolerance to IRI for consistency in mice with microvesicular steatosis using a choline-deficient (CD) diet. (17) However, it was not reported whether their use of the CD diet resulted in obesity or metabolic derangements. Although plasma AST concentration was significantly higher in CD mice compared with lean controls, the extent of necrosis trended toward an increase but was not statistically different. (17) In another study by Llacuna et al., the authors used a high-cholesterol diet to induce microvesicular steatosis. (36) However, this did not result in increased hepatic triglyceride content. It is possible that cholesterol accumulation results in increased sensitivity to IRI. (36) Lastly, Kato et al. report poor tolerance to ischemia reperfusion after 5 or 8 weeks on a 60% HFD, which induced microvesicular and macrovesicular steatosis, respectively. (35) These previous studies are in general agreement with the present study using 2 HFDs that result in increased hepatic triglyceride content and exacerbated IRI in mice.
Although the Western diet-fed mice had small areas of macrovesicular steatosis, this represented <10% of the liver, whereas microvesicular steatosis represented 60.4% of the liver. One study noted that the presence of mild macrovesicular steatosis (0%-20% steatosis) had comparable longterm outcomes and plasma parameters as donor livers with no steatosis, whereas the presence of moderate macrovesicular steatosis (20%-50%) had significantly higher peak ALT concentrations following transplantation. (37) Hence, our use of the Western diet generates a consistent model of hepatic microvesicular steatosis and thus provides an accurate representation of microvesicular steatosis and its tolerance to IRI. We prefer this model to the HTF-C or other high-fat/high-fructose diets to dissect the mechanisms and test potential therapies. Although not perfect, this diet contains a more physiologic fat, cholesterol, and fructose composition and produces obesity and insulin resistance compared with other diets currently in use.
We identified several parameters that were biomarkers for enhanced IRI in steatotic livers, including the established marker ALT. Plasma ALT levels were significantly higher in both groups of HFD-fed mice compared with LF control mice at all reperfusion time points. This is congruent with previous clinical studies (19, 20, 24) as well as rodent studies. (13, 14, (38) (39) (40) (41) Although plasma AST levels were not different among the 3 groups at 4 hours of reperfusion following I/R surgery, ALT is much more specific for hepatocellular injury as AST rise can be attributed to cardiac injury, skeletal injury, and/or hemolysis. (42) (43) (44) Consistent with previous studies of hepatic steatosis and IRI, (14, 40) we were also able to demonstrate higher plasma TNF-a and IL6 concentrations in HFD-fed mice after I/R, which is consistent with an overall proinflammatory state. This supports the theory that steatotic livers may be more susceptible to IRI because of overproduction of inflammatory cytokines. Hepatic IL6 expression was increased in the HFD-fed mice following I/R surgery, but we did not detect any differences in hepatic expression of TNF-a or IL1b following I/R surgery among the 3 different diets. The disconnect between TNF-a concentrations in circulation and tissue expression suggests that posttranscriptional mechanisms affect the concentration in circulation. Given that TNF-a cleavage by matrix metalloproteases is well known to be a regulated step that controls its release (45) and that the presence of soluble receptors in blood can affect the half-life of the circulating cytokine, (46) it is potentially not surprising that mRNA does not track with protein. It is also possible that other tissues are contributing to the TNF-a in circulation.
Although IRI is largely unavoidable in most liverrelated surgeries, the mechanism by which it leads to graft dysfunction is not fully understood. Although the initial ischemic insult can result in direct cell injury and death, the bulk of the injury occurs during the reperfusion phase in which a sustained proinflammatory response results in a robust generation of inflammatory cytokines and reactive oxygen species. (47) We report a novel and interesting finding in which the HTF-C-and Western diet-fed mice had higher levels of necroptosis markers, RIPK3, RIPK1, and MLKL, compared with LF control mice following I/R surgery. The role of necroptosis in liver injury has been examined in both rodent models as well as clinical studies. (48, 49) RIPK3 expression has been found to be elevated in mouse models of liver injury (50) as well as human subjects with liver disease. (51) To our knowledge, we are not aware of other studies showing increased expression of necroptosis markers in the setting of hepatic steatosis and IRI. Additionally, recent studies in hepatic (52) and cardiac IRI (48, 53) have also demonstrated an elevation in RIPK3 and attenuation of injury using necroptosis inhibitors. Although RIPK3 may represent an excellent biomarker for abnormal or exaggerated IRI, its exact role in these models is not yet fully elucidated. For instance, in a recent publication, Roychowdhury et al. demonstrate increased susceptibility to HFD-induced liver injury in RIPK3 knockout mice (RIPK3-/-), (54) whereas 2 previous publications using the MCD diet have shown RIPK3-/-to be protective. (50, 51) RIPK3 deficiency may also be protective in the context of ethanolinduced liver injury. (55) It is possible that the differences may be secondary to experimental paradigm or dietary or mouse strain differences. (49, 56) In the future, further in vitro and in vivo studies using genetic knockouts and small molecule inhibitors will be needed to elucidate the role of RIPK3, RIPK1, and MLKL in hepatic IRI in the setting of hepatic steatosis and determine whether targeting necroptotic signaling is a potentially viable strategy for reducing IRI.
There are several limitations to the work presented herein. A potential weakness in our study is the absence of female mice in the study design. In the future, it will be useful to use both female and male mice in order to detect possible sex differences in the response to HFD or to IRI. Decreasing the length of time that mice are maintained on the studied HFDs may produce less steatosis and allow for investigation of milder forms of steatosis in IRI. Shorter duration on Western diet may also eliminate the small percentage of macrovesicular steatosis and create a pure microvesicular steatosis model. Future studies may also benefit from studying longer reperfusion time points to address longterm survival and outcomes related to liver function and hepatic regeneration. It will also be interesting to use this model system to evaluate the effectiveness of potential therapeutic interventions on these outcomes. Additionally, as always, findings in rodent studies should be applied with caution to the clinical setting. Nevertheless, these data suggest that steatotic livers with microvesicular steatosis due to a fairly physiologic (42% fat) diet are more susceptible to IRI and that use of these organs for transplantation may be harmful. Further investigation into the pathogenic mechanisms may allow us to find new therapeutic targets in the future.
In summary, we have successfully used 2 different models of diet-induced hepatic steatosis to assess its impact on hepatic IRI. We have shown that the presence of steatosis exacerbates IRI as measured by plasma ALT, inflammatory cytokines, and necroptosis markers. Furthermore, histological evaluation demonstrates more extensive necrotic injury in the presence of hepatic steatosis following IRI. Through the use of 2 different diets producing mixed macrovesicular and microvesicular versus predominantly microvesicular hepatic steatosis, we were able to assess whether or not the response to IRI may be different depending on the pattern of steatosis. This distinction will be a valuable tool for future studies evaluating differences in mechanism of injury in the setting of microvesicular steatosis and mixed steatosis.
